Asset

Boron

Emergent BioSolutions Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00636519phase1completed2008-02-012009-10-01Emergent BioSolutionsBotulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

FDA applications (1)

ApplicationTypeApplicant
BLA 125462BLAEmergent BioSolutions Canada Inc.

Marketed products (1)

  • Bat